Comparative Immunogenicity Evaluation of Characterized Chitosan-Based and Other Adjuvants for Inactivated Influenza Vaccines

Chitosan-based adjuvants combine effectiveness, safety and economic feasibility and thus are quite promising for enhancement of influenza control via vaccination, however, problems of characterization and reproducibility remain unresolved; data on relations between physical-chemical characteristics (PCC) of the polymer and immunogenicity of chitosan-based adjuvants, as well as comparative evaluation with other adjuvants are needed. Groups of mice were immunized intramuscularly with inactivated influenza vaccines based on A/California/07/2009 (H1N1) strain with characterized adjuvants based on chitosan with varying PCC (molecular mass 700 and 10 kDa, deacetylation degree 85%; HMC and LMC, respectively) and its derivative (succinylated chitosan (SC)). Experimental formulations were also studied: an «oil-in-water» emulsion (ME) and a multi-component adjuvant (MS). Different adjuvants increased immunogenicity of the inactivated influenza vaccines by hemagglutinin inhibiting sera antibodies in varying patterns. HMC was more immunogenic than LMC, whereas SC even reduced immunogenicity of the vaccine. HMC was comparable to MS by immunogenicity, and LMC - to ME. PCC of chitosan and its derivatives play an important role in immunogenicity of the respective adjuvants, and perspective and characterized chitosan-based adjuvants are comparable or even more immunogenic than adjuvants from other groups.

грипп, вакцина, адъювант, хитозан, доклинические исследования, иммуногенность, influenza, vaccine, adjuvant, chitosan, preclinical trials, immunogenicity

1. WHO. Vaccines against influenza WHO position paper. November 2012. WER. 2012; 47: 461 – 476.

2. WHO. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. WER. 2015; 42: 561 – 571.

3. Vasiliev Y.M. Directions of enhancement for influenza vaccines. Physician. 2014; 8: 12 – 14 (in Russian).

4. Vasiliev Y.M. Neuraminidase inhibitors for specific prophylaxis and therapy of influenza. Physician. 2014; 2: 17 – 19 (in Russian).

5. Kashirina O.S., Vasiliev Y.M. Live attenuated and inactivated influenza vaccines: data from direct comparative studies. Journal of Microbiology. Moscow; 2014; 1: 103 – 119 (in Russian).

6. Chernikova M.I., Vasiliev Y.M. Adjuvanted influenza vaccines: data from direct comparative studies. Journal of Microbiology. Moscow; 2015; 5: 88 – 102 (in Russian).

7. Vasiliev Y. Chitosan-based vaccine adjuvants: incomplete characterization complicates preclinical and clinical evaluation. Expert Review of Vaccines. 2015; 1: 37 – 53.

8. WHO. Manual for the laboratory diagnosis and virological surveillance of influenza. 2011.

9. Khasanova L.M., Il’ina A.V., Varlamov V.P., Sinitsyna O.A., Sinitsyn A.P. Depolymerization of chitosan using an enzyme complex produced by Myceliophthora sp. Applied biochemistry and microbiology. 2014; 4: 422 – 428 (in Russian).

10. Wang W., Bo S., Li S., Qin W. Determination of the Mark-Houwink equation for chitosans with different degrees of deacetylation. International Journal of Biological Macromolecules. 1991; 5: 281 – 285.

11. Hirai A., Odani H., Nakajima A. Determination of degree of deacetylation of chitosan by 1H NMR spectroscopy. Polymer Bulletin. 1991; 1: 87 – 94.

12. Scherlieβß R., Buske S., Young K., Weber B., Rades T., Hook S. In vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations. Vaccine. 2013; 42: 4812 – 4819.

13. Chang H., Li X., Teng Y., Liang Y., Peng B., Fang F. et al. Comparison of adjuvant efficacy of chitosan and aluminum hydroxide for intraperitoneally administered inactivated influenza H5N1 vaccine. DNA and Cell Biology. 2010; 9: 563 – 568.